Drugs / iNK cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06747832 | Dec 2024 → Jun 2026 overdue | small cell lung carcinoma | Guangzhou Ruixin Biotechnological Co., LTD | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT06702098 | Nov 2024 → Aug 2026 overdue | acute myeloid leukemia | Guangzhou Ruixin Biotechnological Co., LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iNK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06747832 ↗ |
| Action | Deplete | “could recognize and kill a wide range of cells in distress, particularly tumour cells and cells infected with viruses.” NCT06702098 ↗ |
| Modality | Cell therapy | “Induced pluripotent setm cells(iPSCs) derived NK cells have better proliferative capacity and homogeneity than donor peripheral blood or umbilical cord blood derived NK cells.” NCT06747832 ↗ |
| Route | Intravenous | “Intravenous infusion of iNK cells is given to the subject” NCT06702098 ↗ |